Literature DB >> 15699627

Superior activity of the type C class of ISS in vitro and in vivo across multiple species.

Jason D Marshall1, Karen L Fearon, Debbie Higgins, Edith M Hessel, Holger Kanzler, Christi Abbate, Priscilla Yee, Josh Gregorio, Tracy Dela Cruz, Jennifer O Lizcano, Alya Zolotorev, Hazel M McClure, Kathleen M Brasky, Krishna K Murthy, Robert L Coffman, Gary Van Nest.   

Abstract

CpG-C are a novel class of CpG motif-containing immunostimulatory sequences (ISS) that includes both a 5'-TCG element and a CpG-containing palindrome. CpG-C drive all known ISS activities and, in particular, are potent enhancers of IFN-alpha from plasmacytoid dendritic cells (PDCs). In our examination of CpG-C sequence requirements, we determined that optimal IFN-alpha-inducing activity could be achieved with longer palindromes. Longer palindromes also correlated with maintenance of the double-stranded (ds) form despite concentration and pH changes, indicating a preference for ds oligodeoxynucleotides (ODNs) by the ISS-induced signaling mechanism for IFN-alpha synthesis. This correlation did not hold for all arms of the ISS-induced immune response, since we did not observe increased B cell activity with the longer palindrome CpG-C ODNs. We further demonstrated that CpG-C retained activity in an in vitro primate system and induced the expression of several cytokines and IFN-alpha-inducible genes when CpG-C were administered in vivo to mice and primates. In conclusion, we have shown CpG-C to exert several types of immune functions across multiple species, and this novel class is thus an attractive candidate for ISS-based therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699627     DOI: 10.1089/dna.2005.24.63

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  22 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Human innate responses and adjuvant activity of TLR ligands in vivo in mice reconstituted with a human immune system.

Authors:  Liang Cheng; Zheng Zhang; Guangming Li; Feng Li; Li Wang; Liguo Zhang; Sandra M Zurawski; Gerard Zurawski; Yves Levy; Lishan Su
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

3.  Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.

Authors:  Shu Wang; Jose Campos; Marilena Gallotta; Mei Gong; Chad Crain; Edwina Naik; Robert L Coffman; Cristiana Guiducci
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

4.  TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS.

Authors:  Niranjan B Butchi; Tyson Woods; Min Du; Timothy W Morgan; Karin E Peterson
Journal:  Am J Pathol       Date:  2011-06-14       Impact factor: 4.307

5.  CpG-C immunotherapeutic efficacy is jeopardized by ongoing exposure to stress: potential implications for clinical use.

Authors:  Yael Goldfarb; Ben Levi; Liat Sorski; Dan Frenkel; Shamgar Ben-Eliyahu
Journal:  Brain Behav Immun       Date:  2010-07-23       Impact factor: 7.217

6.  Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha.

Authors:  Jason D Marshall; Darren S Heeke; Christi Abbate; Priscilla Yee; Gary Van Nest
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

7.  Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Authors:  Shannon S Martin; Russell R Bakken; Cathleen M Lind; Patricia Garcia; Erin Jenkins; Pamela J Glass; Michael D Parker; Mary Kate Hart; Donald L Fine
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

8.  A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.

Authors:  A Ray; Z Tian; D S Das; R L Coffman; P Richardson; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2014-01-30       Impact factor: 11.528

9.  CpG-C oligodeoxynucleotides limit the deleterious effects of beta-adrenoceptor stimulation on NK cytotoxicity and metastatic dissemination.

Authors:  Yael Goldfarb; Marganit Benish; Ella Rosenne; Rivka Melamed; Ben Levi; Ariella Glasner; Shamgar Ben-Eliyahu
Journal:  J Immunother       Date:  2009-04       Impact factor: 4.456

10.  Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization.

Authors:  Caitlin D Lemke-Miltner; Sue E Blackwell; Chaobo Yin; Anna E Krug; Aaron J Morris; Arthur M Krieg; George J Weiner
Journal:  J Immunol       Date:  2020-01-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.